(Angiosarcoma) Is Carotuximab Plus Pazopanib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- April 18, 2022
- Reading time: 1 minute
On March 31, 2022, Robin L. Jones et al. from Royal Marsden Hospital and Institute of Cancer Research published in JAMA Oncology the efficacy and safety results of the anti-CD105 antibody carotuximab plus the multikinase inhibitor pazopanib in advanced angiosarcoma from the TAPPAS Phase 3 trial.
Trial Design
This was an international, multicenter, randomized Phase 3 trial enrolling advanced angiosarcoma patients (N=123), randomized to:
- Carotuximab group: Carotuximab 10 mg/kg once weekly + pazopanib 800 mg once daily
- Pazopanib group: Pazopanib 800 mg once daily
Treatment continued until disease progression or unacceptable toxicity. Primary endpoint: PFS. Secondary endpoints: ORR, OS.
Patient characteristics (114 evaluable patients — pazopanib N=53, carotuximab N=61):
- Female: 61% (N=69)
- Median age: 68 years (range 24–82)
Efficacy Results
Median PFS (primary endpoint):
- Pazopanib group: 4.3 months
- Carotuximab group: 4.2 months — No significant difference between the two arms.
Safety Profile
Most common adverse events (Pazopanib vs. Carotuximab):
- Fatigue: 55% / 61%
- Headache: 23% / 64%
- Diarrhea: 51% / 57%
- Nausea: 49% / 48%
- Vomiting: 23% / 38%
- Anemia: 9% / 44%
- Epistaxis: 4% / 56%
- Hypertension: 55% / 36%
Conclusions
Based on the TAPPAS trial results, Robin L. Jones et al. concluded that carotuximab plus pazopanib did not significantly improve PFS compared to pazopanib monotherapy in advanced angiosarcoma patients.
Source: https://jamanetwork.com/journals/jamaoncology/fullarticle/2790727
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4